Mesenchymal stem cell therapy for chronic major ischemic stroke

Takeaway

  • The STARTING-2 study found no evidence to suggest that treatment with intravenous preconditioned autologous mesenchymal stem cells (MSCs) improves 90-day modified Rankin Scale (mRS) outcomes in patients with chronic ischemic stroke.

Why this matters

  • The potential application of stem cell therapy for chronic stroke is of keen interest.
  • A previous incarnation of the STARTING-2 study (STARTING) used fetal bovine serum (FBS) to expand autologous MSCs for treatment but encountered efficacy limitations.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.